Lung Cancer

There are a number of reasons why patients with cancer are encouraged to enroll in clinical trials, Dr. Michael J. Pishvaian explained.

Camrelizumab combo doubled the five-year survival rate in advanced squamous lung cancer, reducing mortality risk by 43%, in a Phase 3 trial.

Tagrisso is associated with positive outcomes among patients with unresectable stage 3 EGFR-mutant non-small cell lung cancer.

The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 trial data showed.

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% disease control rate.

Treatment with CAN-2409, an off-the-shelf immunotherapy, elicited responses among patients with pretreated stage 3/4 non–small cell lung cancer.

EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach this stage.

Positive preliminary data from the phase 1b/2 trial evaluating Olvi-Vec in small cell lung cancer have been announced.

The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced non-small cell lung cancer.

An application was submitted to the European Medicines Agency seeking approval for treatment with sugemalimab in stage 3 NSCLC following chemoradiotherapy.

Gavreto is recommended as a first-line treatment for metastatic RET fusion-positive, metastatic non-small cell lung cancer, with potential severe side effects.

Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will be presented this month.

Our longtime editor-in-chief offers advice to his successor while discussing the news and education CURE magazine provides for patients with cancer, families and caregivers.

Life-threatening lung cancer has taught me many valuable lessons and made my new normal so fulfilling.

Among patients with resectable non-small cell lung cancer, Opdivo plus Yervoy has displayed potential long-term clinical benefits versus chemotherapy.

The FDA has approved Imfinzi for some adults with limited-stage small cell lung cancer.

An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung cancer.

The FDA granted its first approval for a systemic therapy for patients with non-small cell lung cancer with an Neuregulin 1 gene fusion.

On the heels of two FDA approvals in lung cancer treatments, what innovations are next?

The first patient with small cell lung cancer has been dosed in a trial of peluntamig (PT217) combined with chemotherapy.

After realizing that a stronger support system would have helped me emotionally and spiritually in my cancer journey, I committed myself to being there for my cousin.

Datroway demonstrated durable antitumor activity and an acceptable safety profile in advanced NSCLC with actionable genomic alterations, including EGFR and ALK subgroups.

Neoadjuvant Opdivo with platinum-doublet chemo had a statistically significant and clinically meaningful improvement versus chemo alone in resectable NSCLC.

Zongertinib, an investigational treatment for HER2-mutant advanced NSCLC, has received FDA priority review, showing positive results and favorable safety.